v3.23.3
Collaborations (Tables)
 9 Months Ended
Sep. 30, 2023
Janssen Biotech Inc.  
Collaborative and license agreements  
Schedule of profit and cost sharing relationship The following table shows the profit and cost sharing relationship between Janssen and AbbVie:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2023202220232022
United States - Janssen's share of profits (included in cost of products sold)$316 $398 $925 $1,210 
International - AbbVie's share of profits (included in net revenues)230 286 711 868 
Global - AbbVie's share of other costs (included in respective line items)59 63 171 196 
Genentech, Inc.  
Collaborative and license agreements  
Schedule of profit and cost sharing relationship The following table shows the profit and cost sharing relationship between Genentech and AbbVie:
Three months ended
September 30,		Nine months ended
September 30,
(in millions)2023202220232022
Genentech's share of profits, including royalties (included in cost of products sold)$225 $204 $641 $578 
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)13 10 32 27 
AbbVie's share of development costs (included in R&D)24 29 82 87